Calyxt Reports Financial Results for First Quarter 2018

MINNEAPOLIS & ST. PAUL, Minn.--(BUSINESS WIRE)-- Calyxt, Inc. (NASDAQ: CLXT), a consumer-centric, food- and agriculture-focused company, today announced its results for the three-month period ended March 31, 2018.
Investor Call Details

Calyxt will host an investor call on May 8, 2018 at 8:00 am Eastern Time – 7:00 am Central Time to discuss its financial results and provide a general business update.

The live dial-in information for the conference call is:

US & Canada only: 877-407-9747
International: 412-902-0044

In addition, a replay of the call will be available until June 8, 2018 by calling 877-660-6853 (Toll Free US & Canada); 201-612-7415 (Toll Free International). The archived webcast of this event may be accessed through the Calyxt website.

Webcast URL (Archived for 6 months):

“We continue to advance our mission to deliver good-for-you foods in a good-for-everyone way. We are proud of our progress towards evolving the nutrition of food to deliver high quality, trusted ingredients, that are traceably produced for complete transparency. We are transforming the Company, as we transition into a commercial entity with a powerful R&D engine that will expand once we move to our new state-of-the-art concept to fork facility. We have received USDA non-regulated status for seven products and prepared our first product for commercialization. We look forward to continued commercial and supply chain successes for the rest of 2018 while we continue to grow our capability to deliver healthier food to consumers,” said Federico Tripodi, Calyxt Chief Executive Officer.

Corporate highlights

Expansion of total acreage for high-oleic soybean product launch

Calyxt announced on April 5, 2018 that the Company has further expanded its total acreage with farmers across the northern United States for its high-oleic soybean variety. Calyxt has contracted over 16,000 acres with 75 farmers in the Midwest. Overall, these growers collectively farm over 200,000 acres, half of which are expected to produce soybeans. Around 17% of the soybeans that are anticipated to be planted consist of Calyxt’s high-oleic variety. Over 90% of farmers that planted Calyxt’s high-oleic soybeans in 2017 have renewed their Calyxt high-oleic soybeans contracts this year. Furthermore, on average, each repeat farmer is more than doubling his or her Calyxt acres year-over-year. Calyxt successfully launched a Brand Ambassador Program which enrolled progressive, high-quality growers to be early adopters and advocates of gene editing technology.

Planting of high-oleic soybeans

Farmers enrolled in the Calyxt high-oleic soybean program have started planting. The planting will pick up speed over coming weeks and likely to be completed by mid-June.

Calyxt’s high fiber wheat deemed non-regulated by USDA

Calyxt announced on March 21, 2018 that the Company’s high fiber wheat product has been declared a non-regulated article under the “Am I Regulated?” process by Biotechnology Regulatory Services of the Animal and Plant Health Inspection Service (APHIS), an agency of the United States Department of Agriculture (USDA). This is Calyxt’s first consumer-centric wheat product and second wheat product (following Calyxt’s powdery mildew resistant wheat, which received non-regulated status by the USDA in February 2016), and seventh product overall, to be given this designation. High fiber wheat may be the next product to market with anticipated commercialization as early as 2020-21.

Twenty small to large food company customers engaged across food services and food ingredient applications

Engagements with food company customers continue to grow. In the first quarter of 2018, Calyxt added 8 more customers taking the total number of customer engagements to 20. These customers are evaluating Calyxt high-oleic soybean oil for end-use applications such as frying potatoes (chips, french fries), meats, snacks (salty and healthy), baking, nut butter and vegan products.

New concept-to-fork facility in Roseville, Minn., on track for completion in the second quarter of 2018

Calyxt will soon open its nearly 40,000-square-foot concept-to-fork facility on an 11-acre site that will house a test kitchen, state-of-the-art research labs and the Company’s headquarters. The new facility is being constructed adjacent to Calyxt’s recently completed 11,000+square-foot greenhouse facility and existing outdoor demonstration plots.

Financial Highlights

Cash and cash equivalents were $50.7 million at March 31, 2018. We intend to continue to judiciously manage the use of cash and expect to have sufficient cash to fund the business for a significant portion of 2019. Cellectis remains our majority shareholder with 79.1% of our common stock as of March 31, 2018.

For the three months ended March 31, 2018, we incurred losses from operations of $4.4 million, and used net cash in operating activities of $6.6 million. Net decrease in cash for the first quarter was $6.0 million. The first quarter cash spend includes spending on high-oleic soybean seed production to support our expected Spring 2018 planting of high-oleic soybeans.

Looking forward for the rest of 2018, we anticipate that our operating cash spend will be in the range of $2.0 to $2.2 million per month excluding working capital for grain purchases in the later part of 2018. Cash will be used to expand our R&D team to advance key products in the portfolio and continue to build our commercial capabilities.


Calyxt, Inc.

Condensed Balance Sheets

(Amounts in Thousands, Except Share Data and Per Share Data)

    March 31,

31, 2017

Current assets:          
Cash and cash equivalents   $ 50,703   $ 56,664  
Trade accounts receivable      
Due from related parties   47   167  
Prepaid expenses and other current assets   2,080   626  
Total current assets   52,830   57,457  
Property and equipment, net   18,767   14,353  
Other long-term assets   270   357  
Total assets   $ 71,867   $ 72,167  
Liabilities and stockholders’ equity          
Current liabilities:          
Due to related parties   $ 742   $ 1,350  
Accounts payable   441   1,023  
Accrued salaries, wages, and other compensation   490   945  
Accrued liabilities   1,256   893  
Current deferred revenue   43   43  
Total current liabilities   2,972   4,254  
Non-current deferred revenue   278   289  
Finance lease obligations   14,757   10,148  
Total liabilities   18,007   14,691  
Stockholders’ equity:          

Common stock, $0.0001 par value; 275,000,000 shares authorized, 27,954,781 and
27,718,780 shares issued and outstanding as of March 31, 2018 and December
31,2017, respectively

  3   3  
Preferred stock, $0.0001 par value; 50,000,000 shares authorized, no shares
issued or outstanding as of March 31, 2018 and December 31, 2017 respectively
Additional paid-in capital   112,775   112,021  
Accumulated deficit   (58,918)   (54,548)  
Total stockholders’ equity   53,860   57,476  
Total liabilities and stockholders’ equity   $ 71,867   $ 72,167  

Calyxt, Inc.

Condensed Statements of Operations


(Amounts in Thousands except Shares Outstanding and Per Share Amounts)

    Three Months Ended
March 31
    2018   2017  
Revenue   $ 11   $ 55  
Operating expenses:          
Cost of revenue      
Research and development   1,093   1,266  
Selling, general, and administrative   3,214   1,578  
Total operating expenses   4,307   2,844  
Loss from operations   (4,296)   (2,789)  
Interest expense, net   (68)   (14)  
Foreign currency transaction loss   (6)   (29)  
Loss before income taxes   (4,370)   (2,832)  
Income tax expense      
Net loss   $ (4,370)   $ (2,832)  
Basic and diluted loss per share   $ (0.16)   $ (0.14)  
Weighted average shares outstanding—basic and diluted   27,851,162   19,600,000  

Calyxt, Inc.

Condensed Statement of Stockholders’ Equity

(Amounts in Thousands except Shares Outstanding)











Balances at December 31, 2017   27,718,780   $ 3   $ 112,021   $ (54,548)   $ 57,476  
Net loss         (4,370)   (4,370)  

Common shares issued upon
exercise of options and other

  236,001     714     714  
Stock-based compensation       40     40  
Balances at March 31, 2018 (unaudited)   27,954,781   $ 3   $ 112,775   $ (58,918)   $ 53,860  

Calyxt, Inc.

Condensed Statements of Cash Flows

(Amounts in Thousands)

    Three Months Ended
March 31,
    2018   2017  
Operating activities      
Net loss   $ (4,370)   $ (2,832)  

Adjustments to reconcile net loss to net cash used in operating

Depreciation   156   133  
Stock-based compensation   40   134  
Unrealized transaction gain (loss) on related party activity   8   (27)  
Changes in operating assets and liabilities:          
Trade accounts receivable     110  
Due to/from related parties   (496)   490  
Prepaid expenses and other assets   (880)   (426)  
Accounts payable   (581)   337  
Accrued salaries, wages, and other compensation   (456)   (89)  
Accrued liabilities   25   418  
Deferred revenue   (11)   45  
Net cash used in operating activities   (6,565)   (1,707)  
Investing activities          
Purchases of property and equipment   (41)   (312)  
Net cash used in investing activities   (41)   (312)  
Financing activities          
Deferred costs   (69)    
Proceeds from the exercise of stock options   714    
Net cash provided by financing activities   645    
Net decrease in cash and cash equivalents   (5,961)   (2,019)  
Cash and cash equivalents—beginning of period   56,664   5,026  
Cash and cash equivalents—end of period   $ 50,703   $ 3,007  
Supplemental cash flow information          
Interest paid   124   14  
Supplemental non-cash investing and financing transactions:          
Property and equipment included in financing lease obligation   4,529    
Deferred costs in accounts payable and accrued liabilities   417      

About Calyxt

Calyxt, Inc. is a consumer-centric, food- and agriculture-focused company. Calyxt is pioneering a paradigm shift to deliver healthier food ingredients, such as healthier oils and high fiber wheat, for consumers and crop traits that benefit the environment and reduce pesticide applications, such as disease tolerance, for farmers. Calyxt develops non-transgenic crops leveraging processes that occur in nature by combining its leading gene-editing technology and technical expertise with its innovative commercial strategy. Calyxt is located in Minneapolis-St. Paul, MN, and is listed on the Nasdaq market (ticker: CLXT).

For further information please visit our website:
Calyxt™ and the corporate logo are trademarks owned by Calyxt, Inc.
TALEN® is a registered trademark owned by the Cellectis S.A.

Calyxt Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” the negative of these terms and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties and assumptions about us, may include projections of our future financial performance, our anticipated growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements, including those factors discussed under the caption entitled “Risk Factors” in our Annual Report on Form 10-K, along with our other filings with the U.S. Securities and Exchange Commission. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by applicable laws.



Jennifer Moore, 917-580-1088
VP Communications
KCSA Strategic Communications
Caitlin Kasunich, 212-896-1241
Nick Opich, 212-896-1206
Investor Relations
Simon Harnest, 646-385-9008
VP Corporate Strategy and Finance


Source: Calyxt

Back to news